These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3652512)

  • 1. Protective effect of myasthenic immunoglobulins against the lethal toxicity of alpha bungarotoxin.
    Vernet-der Garabedian B; Bach JF; Morel E
    Clin Exp Immunol; 1987 Apr; 68(1):130-7. PubMed ID: 3652512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity of antibodies directed against the alpha-bungarotoxin binding site on human acetylcholine receptor and severity of myasthenia gravis.
    Vernet-der Garabedian B; Morel E; Bach JF
    J Neuroimmunol; 1986 Jul; 12(1):65-74. PubMed ID: 3711314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Heterogeneity of antibodies blocking the binding of bungarotoxin to the acetylcholine receptor in myasthenia].
    Vernet-der-Garabédian B; Morel E; Bach JF
    C R Acad Sci III; 1984; 298(16):449-56. PubMed ID: 6428718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. alpha-Bungarotoxin displacing antibody in myasthenia gravis.
    Barkas T; Simpson JA
    J Clin Lab Immunol; 1982 Nov; 9(2):113-7. PubMed ID: 7154056
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myasthenic sera recognize the human acetylcholine receptor bound to thymopoietin.
    Morel E; Vernet-der Garabedian B; Raimond F; Audhya TK; Goldstein G; Bach JF
    Eur J Immunol; 1987 Aug; 17(8):1109-13. PubMed ID: 3622601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiple forms of anti-acetylcholine receptor antibody in myasthenia gravis.
    Mittag T; Massa T; Kornfeld P; Papatestas A; Bender A; Genkins G
    Muscle Nerve; 1981; 4(1):16-25. PubMed ID: 6164920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Antibodies in myasthenia gravis].
    Eymard B
    Rev Neurol (Paris); 2009 Feb; 165(2):137-43. PubMed ID: 19162288
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-MuSK patient antibodies disrupt the mouse neuromuscular junction.
    Cole RN; Reddel SW; Gervásio OL; Phillips WD
    Ann Neurol; 2008 Jun; 63(6):782-9. PubMed ID: 18384168
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immunity in myasthenia gravis: biochemical characterization of acquired antireceptor antibodies and clinical correlations.
    Tindall RS
    Ann Neurol; 1981 Nov; 10(5):437-47. PubMed ID: 7305297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation.
    Drachman DB; Angus CW; Adams RN; Michelson JD; Hoffman GJ
    N Engl J Med; 1978 May; 298(20):1116-22. PubMed ID: 643030
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of alpha-bungarotoxin binding to acetylcholine receptors by antisera from animals with experimental autoimmune myasthenia gravis.
    Claudio T; Raftery MA
    J Supramol Struct; 1980; 14(3):267-79. PubMed ID: 6971372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antigenic modulation of human myotube acetylcholine receptor by myasthenic sera. Serum titer determines receptor internalization rate.
    Tzartos SJ; Sophianos D; Zimmerman K; Starzinski-Powitz A
    J Immunol; 1986 May; 136(9):3231-8. PubMed ID: 3958494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of the main immunogenic region of acetylcholine receptor in myasthenia gravis. An Fab monoclonal antibody protects against antigenic modulation by human sera.
    Tzartos SJ; Sophianos D; Efthimiadis A
    J Immunol; 1985 Apr; 134(4):2343-9. PubMed ID: 3973387
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accessibility to antibodies of acetylcholine receptors in the neuromuscular junction.
    Zurn AD; Fulpius BW
    Clin Exp Immunol; 1976 Apr; 24(1):9-17. PubMed ID: 949876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A modified assay for antibody against the nicotinic acetylcholine receptor in myasthenia gravis.
    Dwyer DS; Bradley RJ; Oh SJ; Kemp GE
    Clin Exp Immunol; 1979 Sep; 37(3):448-51. PubMed ID: 509779
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Heterogeneity of acetylcholine receptors: different forms of receptor distinguished by alpha-bungarotoxin kinetics and by antibody binding properties.
    Massa T; Mittag TW
    J Pharmacol Exp Ther; 1983 Nov; 227(2):340-8. PubMed ID: 6631716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of myasthenic IgG on degradation of junctional acetylcholine receptor.
    Takeo G; Motomura M; Mats H; Ohishi K; Yoshimura T; Tsujihata M; Nagataki S
    Muscle Nerve; 1993 Aug; 16(8):840-8. PubMed ID: 8332137
    [TBL] [Abstract][Full Text] [Related]  

  • 18. beta-Bungarotoxin binding protein is immunogenic but lacks myasthenogenicity in rats.
    Qiao J; Wang ZY; Link H
    J Neurol Sci; 1994 Feb; 121(2):190-3. PubMed ID: 8158214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Electrophysiological effects of myasthenic serum factors studied in mouse muscle.
    Lerrick AJ; Wray D; Vincent A; Newsom-Davis J
    Ann Neurol; 1983 Feb; 13(2):186-91. PubMed ID: 6830177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A radioimmunoassay for the quantitative evaluation of anti-human acetylcholine receptor antibodies in myasthenia gravis.
    Monnier VM; Fulpius BW
    Clin Exp Immunol; 1977 Jul; 29(1):16-22. PubMed ID: 891031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.